A Phase 3 interventional study of Experimental: Tezepelumab and Placebo in Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca. Completed at 112 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.
Among the 83 studies in Nasal Polyps with a site in United States, this one is the 5th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2021, is one of 25 in phase 3, and was the 51st registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Japan, Puerto Rico
Ages 18+
GlaxoSmithKline · Sites in United States, Australia
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Airiver Medical, Inc. · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 27 · Phase 4 10
First in 2005; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 416 is above the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 60 across the 71 interventional studies, 35 across the 12 observational. Of the 54 that completed or were terminated, 41 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 83 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 8 studies filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
8 of the studies in Nasal Polyps with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07681973The Cleveland ClinicCognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training | 2026-12-31 |
| NCT07286201Polyganics BVEvaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF) | 2027-03 |
| NCT07599826Cedars-Sinai Medical CenterActive vs. Passive VR During Office-based ENT Procedures | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 83 studies in Nasal Polyps with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis
This is a multicentre, randomised, double-blind, placebo controlled, parallel group study designed to evaluate the efficacy and safety of tezepelumab in adults with severe, chronic rhinosinusitis with nasal polyposis. Approximately 400 subjects will be randomized globally. Participants will receive tezepelumab, or placebo, administered via subcutaneous injection using the accessorized pre-filled syringe (APFS) every 4 weeks, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12-24 weeks for participants who complete the 52-week treatment period. All participants will have background mometasone furoate nasal spray or equivalent intranasal corticosteroid at a stable dose from Visit 1 and throughout the screening and study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with physician-diagnosed CRSwNP for at least 12 months prior to Visit 1 that have:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tezepelumab subcutaneous injection in an accessorized pre-filled syringe every 4 weeks (Q4W) added to background mometasone furoate (MFNS) or equivalent intranasal corticosteroid (INCS).
Biological: Experimental: Tezepelumab · Drug: Mometasone furoate or equivalent intranasal corticosteroid
Placebo subcutaneous injection in an accessorized pre-filled syringe Q4W added to background MFNS or equivalent INCS.
Other: Placebo · Drug: Mometasone furoate or equivalent intranasal corticosteroid
Tezepelumab subcutaneous injection
Placebo subcutaneous injection
Background MFNS or equivalent INCS at stable dose
Change From Baseline in Total Nasal Polyp Score at Week 52
The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.
Time frame: Baseline to Week 52
Change From Baseline in Bi-weekly Mean Nasal Congestion Score (NCS) at Week 52
The NCS is captured by one item in the NPSD (nasal polyps symptom diary) asking participants to rate the severity of their worst NC over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses from Day -13 to Day 0. Bi-weekly (14-day) mean NCS will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.
Time frame: Baseline to Week 52
Change From Baseline in Bi-weekly Mean Loss of Smell at Week 52
Participant reported sense of smell will be evaluated as part of the NPSD. Loss of smell is captured by the DSS item (difficulty with sense of smell) in the NPSD asking participants to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses to the from Day -13 to Day 0. Bi-weekly (14-day) mean loss of smell will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.
Time frame: Baseline to Week 52
Change From Baseline in SinoNasal Outcome Test 22 (SNOT-22) at Week 52
SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes).
Time frame: Baseline to Week 52
Change From Baseline in Lund Mackay Score Evaluated by CT at Week 52.
The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes).
Time frame: Week 52
Percentage of Participants With Nasal Polyp Surgery Decision and/or Systemic Corticosteroid for Nasal Polyposis up to Week 52
Surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g., polypectomy, endoscopic sinus surgery). Rescue treatment of NP is defined as requiring treatment with systemic corticosteroids (SCS) for at least 3 consecutive days (a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids). Time to first NP surgery decision or SCS for NP = (date of the first NP surgery decision or start date of first SCS for NP use - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.
Time frame: Up to Week 52
Percentage of Participants With Nasal Polyp Surgery Decision up to Week 52
Surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g., polypectomy, endoscopic sinus surgery). Time to first NP surgery decision = (date of the first NP surgery decision - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.
Time frame: Up to Week 52
Percentage of Participants With Systemic Corticosteroids for Nasal Polyposis up to Week 52
Systemic corticosteroids (SCS) for nasal polyposis (NP) is defined as requiring at least 3 consecutive days (a single depo-injectable dose of corticosteroids was considered equivalent to a 3-day course of SCS) for NP. Time to first SCS for NP = (start date of first SCS for NP use - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.
Time frame: Up to Week 52
Change From Baseline in Bi-weekly Mean Nasal Polyposis Symptom Diary Total Symptom Score at Week 52
The participant completed the nasal polyposis symptom diary each morning throughout the study. The participant was asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants were asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, difficulty with sense of smell). Participants reported the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe). A total symptom score (range from 0 to 24) was calculated by taking the sum of the 8 equally weighted symptom items. Higher scores indicate greater symptom severity.
Time frame: Baseline to Week 52
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume (L) in 1 Second at Week 52.
For participants with comorbid asthma and aspirin exacerbated respiratory disease (AERD)/nonsteroidal anti-inflammatory drug exacerbated respiratory disease (NSAID-ERD), difference in change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) in the tezepelumab arm as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of forced expiration.
Time frame: Baseline to Week 52
Change From Baseline Over Time in Nasal Polyp Score Through Week 52.
The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.
Time frame: Baseline to Week 52
Proportion of Participants With ≥1 Point Reduction in the Nasal Polyp Score at Week 52
The Nasal Polyp Score is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy. A participant with ≥1 point reduction in NPS at Week 52 in the absence of SCS for NP, biologic for NP, or NP surgery at or prior to that time point was defined as a responder, otherwise the participant was defined as a non-responder.
Time frame: Baseline to Week 52
Proportion of Participants With ≥2 Point Reduction in the Nasal Polyp Score at Week 52
The Nasal Polyp Score is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy. A participant with ≥2 point reduction in NPS at Week 52 in the absence of SCS for NP, biologic for NP, or NP surgery at or prior to that time point was defined as a responder, otherwise the participant was defined as a non-responder.
Time frame: Baseline to Week 52
Change From Baseline Over Time in Bi-weekly Mean Nasal Congestion Score Evaluated by Nasal Polyposis Symptom Diary Through Week 52.
The NCS is captured by one item in the NPSD (nasal polyps symptom diary) asking participants to rate the severity of their worst NC over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses from Day -13 to Day 0. Bi-weekly (14-day) mean NCS will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.
Time frame: Baseline to Week 52
Change From Baseline in Loss of Smell Evaluated by University of Pennsylvania Smell Identification Test (UPSIT) at Week 52.
The University of Pennsylvania Smell Identification Test is a quantitative test of olfactory function which uses microencapsulated odorants that are released by scratching standardized odour-impregnated test booklets. Scores are based on number of correctly identified odours (score range 0-40, lower scores indicate poorer outcomes).
Time frame: Baseline to Week 52
Change From Baseline in Modified Lund Mackay Score Evaluated by CT at Week 52.
The Modified Lund-Mackay score scoring system was used to provide a semi-quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) on each side were scored. Each sinus on each side was scored based on the percentage of opacification from mucosal thickening according to matrix: (score 0 for 0% Opacification; score 1 for 1-25% Opacification; score 2 for 26-50% Opacification; score 3 for 51-75% Opacification; score 4 for 76-99% Opacification; score 5 for 100% Opacification). The range of total Modified Lund Mackay score is from 0 to 50. Higher scores indicate greater symptom severity.
Time frame: Baseline to Week 52
Change From Baseline in Sinus Severity Score by Quantitative CT Assessment at Week 52
Quantitative assessment of sinus CT image data were used to derive an objective measure of sinus disease burden called sinus severity score. The sinus severity score is defined as: (sinus mucosal volume)/(sinus mucosal volume + sinus air volume)×100%. The range of sinus severity score is 0 to 100. Higher scores indicate greater symptom severity.
Time frame: Baseline to Week 52
Exposure of Systemic Corticosteroids Over 52 Weeks
The number of courses of SCS for NP per year was analysed using a negative binomial model. The response variable was the number of courses of SCS for NP received by a participant over the planned treatment period. The model included treatment group, baseline co-morbid asthma/AERD/NSAID-ERD status, prior NP surgery status, and region as factors. The logarithm of the time at risk (in years) was used as an offset variable, to adjust different follow-up times. Time during a course was not included in the calculation of time at risk.
Time frame: Over 52 weeks
Change From Baseline by Domain of the Nasal Polyposis Symptom Diary Through Week 52
The participant will complete an 11-item nasal polyposis symptom diary each morning throughout the screening, treatment and follow-up periods. The participant is asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants are asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, and difficulty with sense of smell) and symptom impacts (difficulty with sleeping due to nasal symptoms and difficulty with daily activities due to nasal symptoms). Participants report the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe).
Time frame: Baseline to Week 52
Change From Baseline in Nasal Peak Inspiratory Flow Through Week 52.
Nasal peak inspiratory flow evaluation represents a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute.
Time frame: Baseline to Week 52
Change From Baseline in Asthma Control Questionnaire-6 at Week 52.
The Asthma Control Questionnaire is an assessment of asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short acting beta-agonist use). Participants are asked to recall their level of asthma control during the previous week by responding to one bronchodilator use question and 5 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).
Time frame: Baseline to Week 52
Tezepelumab Pharmacokinetics
Serum concentrations of tezepelumab through Week 64. Logarithm transformation was used when calculating geometric mean of serum concentrations. The results were transformed back to original scale.
Time frame: Pre-dose samples at Baseline, Week 4, Week 12, Week 24, Week 36, Week 52, and Week 64
Immunogenicity of Tezepelumab for Non-China Subjects
Anti-drug antibodies (ADA) responses at baseline and post-baseline. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.
Time frame: Pre-dose samples at Baseline to Week 64
Immunogenicity of Tezepelumab for China Subjects
Anti-drug antibodies (ADA) responses at baseline and post-baseline. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.
Time frame: Pre-dose samples at Baseline to Week 64
A total of 416 participants were randomized, 6 of which were removed from analyses due to GCP issues, before study unblinding. The remaining 410 were randomized to either the treatment arm (204 participants) or placebo (206 participants) arms of the double-blind treatment period. Two participants were randomized but not dosed (one was withdrawal by subject, one did not meet inclusion/exclusion criteria). Therefore, 203 participants started in the treatment arm and 205 in the placebo arm.
| Milestone | Tezepelumab | Placebo |
|---|---|---|
| Started | 203 | 205 |
| Completed | 193 | 174 |
| Not completed | 10 | 31 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 8 | 23 |
| Withdrew: Severe incompliance | 0 | 1 |
| Withdrew: Nasal polyp surgery | 0 | 2 |
| Withdrew: Other biologic treatment | 0 | 2 |
The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Total Nasal Polyp Score at Week 52 | -2.458 (-2.681 to -2.234) | -0.380 (-0.611 to -0.148) |
The NCS is captured by one item in the NPSD (nasal polyps symptom diary) asking participants to rate the severity of their worst NC over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses from Day -13 to Day 0. Bi-weekly (14-day) mean NCS will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Bi-weekly Mean Nasal Congestion Score (NCS) at Week 52 | -1.743 (-1.864 to -1.622) | -0.703 (-0.830 to -0.577) |
Participant reported sense of smell will be evaluated as part of the NPSD. Loss of smell is captured by the DSS item (difficulty with sense of smell) in the NPSD asking participants to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses to the from Day -13 to Day 0. Bi-weekly (14-day) mean loss of smell will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Bi-weekly Mean Loss of Smell at Week 52 | -1.261 (-1.382 to -1.139) | -0.255 (-0.378 to -0.133) |
SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes).
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in SinoNasal Outcome Test 22 (SNOT-22) at Week 52 | -45.022 (-48.572 to -41.472) | -17.580 (-21.189 to -13.971) |
The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes).
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Lund Mackay Score Evaluated by CT at Week 52. | -6.270 (-6.740 to -5.799) | -0.569 (-1.046 to -0.093) |
Surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g., polypectomy, endoscopic sinus surgery). Rescue treatment of NP is defined as requiring treatment with systemic corticosteroids (SCS) for at least 3 consecutive days (a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids). Time to first NP surgery decision or SCS for NP = (date of the first NP surgery decision or start date of first SCS for NP use - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.
| Percentage of participants | Tezepelumab | Placebo |
|---|---|---|
| Percentage of Participants With Nasal Polyp Surgery Decision and/or Systemic Corticosteroid for Nasal Polyposis up to Week 52 | 5.7 (1.3 to 15.0) | 31.4 (25.0 to 38.0) |
Surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g., polypectomy, endoscopic sinus surgery). Time to first NP surgery decision = (date of the first NP surgery decision - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.
| Percentage of participants | Tezepelumab | Placebo |
|---|---|---|
| Percentage of Participants With Nasal Polyp Surgery Decision up to Week 52 | 0.5 (0.0 to 2.5) | 22.0 (16.4 to 28.2) |
Systemic corticosteroids (SCS) for nasal polyposis (NP) is defined as requiring at least 3 consecutive days (a single depo-injectable dose of corticosteroids was considered equivalent to a 3-day course of SCS) for NP. Time to first SCS for NP = (start date of first SCS for NP use - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.
| Percentage of participants | Tezepelumab | Placebo |
|---|---|---|
| Percentage of Participants With Systemic Corticosteroids for Nasal Polyposis up to Week 52 | 5.2 (1.1 to 14.7) | 19.3 (14.1 to 25.1) |
The participant completed the nasal polyposis symptom diary each morning throughout the study. The participant was asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants were asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, difficulty with sense of smell). Participants reported the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe). A total symptom score (range from 0 to 24) was calculated by taking the sum of the 8 equally weighted symptom items. Higher scores indicate greater symptom severity.
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Bi-weekly Mean Nasal Polyposis Symptom Diary Total Symptom Score at Week 52 | -10.388 (-11.174 to -9.601) | -3.429 (-4.241 to -2.617) |
For participants with comorbid asthma and aspirin exacerbated respiratory disease (AERD)/nonsteroidal anti-inflammatory drug exacerbated respiratory disease (NSAID-ERD), difference in change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) in the tezepelumab arm as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of forced expiration.
| Liter | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume (L) in 1 Second at Week 52. | 0.022 (-0.065 to 0.108) | 0.027 (-0.055 to 0.108) |
The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.
| Score | Tezepelumab | Placebo |
|---|---|---|
| Week 4 | -1.615 (-1.797 to -1.433) | -0.255 (-0.434 to -0.077) |
| Week 12 | -1.918 (-2.112 to -1.723) | -0.376 (-0.569 to -0.182) |
| Week 24 | -2.104 (-2.310 to -1.899) | -0.314 (-0.522 to -0.106) |
| Week 36 | -2.351 (-2.552 to -2.149) | -0.287 (-0.493 to -0.082) |
| Week 52 | -2.458 (-2.681 to -2.234) | -0.380 (-0.611 to -0.148) |
The Nasal Polyp Score is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy. A participant with ≥1 point reduction in NPS at Week 52 in the absence of SCS for NP, biologic for NP, or NP surgery at or prior to that time point was defined as a responder, otherwise the participant was defined as a non-responder.
| Participants | Tezepelumab | Placebo |
|---|---|---|
| Proportion of Participants With ≥1 Point Reduction in the Nasal Polyp Score at Week 52 | 161 | 64 |
The Nasal Polyp Score is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy. A participant with ≥2 point reduction in NPS at Week 52 in the absence of SCS for NP, biologic for NP, or NP surgery at or prior to that time point was defined as a responder, otherwise the participant was defined as a non-responder.
| Participants | Tezepelumab | Placebo |
|---|---|---|
| Proportion of Participants With ≥2 Point Reduction in the Nasal Polyp Score at Week 52 | 129 | 39 |
The NCS is captured by one item in the NPSD (nasal polyps symptom diary) asking participants to rate the severity of their worst NC over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses from Day -13 to Day 0. Bi-weekly (14-day) mean NCS will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.
| Score | Tezepelumab | Placebo |
|---|---|---|
| Week 2 | -0.379 (-0.438 to -0.319) | -0.192 (-0.251 to -0.133) |
| Week 4 | -0.779 (-0.868 to -0.691) | -0.322 (-0.411 to -0.234) |
| Week 8 | -1.134 (-1.236 to -1.032) | -0.451 (-0.553 to -0.349) |
| Week 12 | -1.270 (-1.376 to -1.164) | -0.607 (-0.714 to -0.500) |
| Week 24 | -1.515 (-1.628 to -1.402) | -0.703 (-0.818 to -0.588) |
| Week 36 | -1.629 (-1.748 to -1.509) | -0.726 (-0.850 to -0.601) |
| Week 48 | -1.735 (-1.856 to -1.613) | -0.721 (-0.847 to -0.594) |
| Week 52 | -1.743 (-1.864 to -1.622) | -0.703 (-0.830 to -0.577) |
The University of Pennsylvania Smell Identification Test is a quantitative test of olfactory function which uses microencapsulated odorants that are released by scratching standardized odour-impregnated test booklets. Scores are based on number of correctly identified odours (score range 0-40, lower scores indicate poorer outcomes).
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Loss of Smell Evaluated by University of Pennsylvania Smell Identification Test (UPSIT) at Week 52. | 9.310 (8.147 to 10.474) | -0.192 (-1.378 to 0.993) |
The Modified Lund-Mackay score scoring system was used to provide a semi-quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) on each side were scored. Each sinus on each side was scored based on the percentage of opacification from mucosal thickening according to matrix: (score 0 for 0% Opacification; score 1 for 1-25% Opacification; score 2 for 26-50% Opacification; score 3 for 51-75% Opacification; score 4 for 76-99% Opacification; score 5 for 100% Opacification). The range of total Modified Lund Mackay score is from 0 to 50. Higher scores indicate greater symptom severity.
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Modified Lund Mackay Score Evaluated by CT at Week 52. | -17.520 (-18.708 to -16.332) | -1.106 (-2.291 to 0.078) |
Quantitative assessment of sinus CT image data were used to derive an objective measure of sinus disease burden called sinus severity score. The sinus severity score is defined as: (sinus mucosal volume)/(sinus mucosal volume + sinus air volume)×100%. The range of sinus severity score is 0 to 100. Higher scores indicate greater symptom severity.
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Sinus Severity Score by Quantitative CT Assessment at Week 52 | -32.754 (-35.047 to -30.461) | -1.978 (-4.267 to 0.310) |
The number of courses of SCS for NP per year was analysed using a negative binomial model. The response variable was the number of courses of SCS for NP received by a participant over the planned treatment period. The model included treatment group, baseline co-morbid asthma/AERD/NSAID-ERD status, prior NP surgery status, and region as factors. The logarithm of the time at risk (in years) was used as an offset variable, to adjust different follow-up times. Time during a course was not included in the calculation of time at risk.
| SCS courses per year | Tezepelumab | Placebo |
|---|---|---|
| Exposure of Systemic Corticosteroids Over 52 Weeks | 0.04 (0.02 to 0.08) | 0.35 (0.23 to 0.55) |
The participant will complete an 11-item nasal polyposis symptom diary each morning throughout the screening, treatment and follow-up periods. The participant is asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants are asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, and difficulty with sense of smell) and symptom impacts (difficulty with sleeping due to nasal symptoms and difficulty with daily activities due to nasal symptoms). Participants report the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe).
| Score | Tezepelumab | Placebo |
|---|---|---|
| Nasal Blockage Week 2 | -0.359 (-0.416 to -0.301) | -0.170 (-0.227 to -0.112) |
| Nasal Blockage Week 4 | -0.744 (-0.831 to -0.656) | -0.298 (-0.385 to -0.211) |
| Nasal Blockage Week 8 | -1.122 (-1.225 to -1.018) | -0.423 (-0.527 to -0.320) |
| Nasal Blockage Week 12 | -1.259 (-1.367 to -1.152) | -0.555 (-0.663 to -0.447) |
| Nasal Blockage Week 24 | -1.502 (-1.617 to -1.387) | -0.678 (-0.795 to -0.561) |
| Nasal Blockage Week 36 | -1.628 (-1.750 to -1.506) | -0.703 (-0.830 to -0.576) |
| Nasal Blockage Week 48 | -1.697 (-1.821 to -1.573) | -0.722 (-0.850 to -0.594) |
| Nasal Blockage Week 52 | -1.759 (-1.882 to -1.636) | -0.697 (-0.825 to -0.569) |
| Nasal Congestion Week 2 | -0.379 (-0.438 to -0.319) | -0.192 (-0.251 to -0.133) |
| Nasal Congestion Week 4 | -0.779 (-0.868 to -0.691) | -0.322 (-0.411 to -0.234) |
| Nasal Congestion Week 8 | -1.134 (-1.236 to -1.032) | -0.451 (-0.553 to -0.349) |
| Nasal Congestion Week 12 | -1.270 (-1.376 to -1.164) | -0.607 (-0.714 to -0.500) |
| Nasal Congestion Week 24 | -1.515 (-1.628 to -1.402) | -0.703 (-0.818 to -0.588) |
| Nasal Congestion Week 36 | -1.629 (-1.748 to -1.509) | -0.726 (-0.850 to -0.601) |
| Nasal Congestion Week 48 | -1.735 (-1.856 to -1.613) | -0.721 (-0.847 to -0.594) |
| Nasal Congestion Week 52 | -1.743 (-1.864 to -1.622) | -0.703 (-0.830 to -0.577) |
| Runny Nose Week 2 | -0.347 (-0.407 to -0.288) | -0.164 (-0.224 to -0.105) |
| Runny Nose Week 4 | -0.676 (-0.757 to -0.595) | -0.239 (-0.320 to -0.158) |
| Runny Nose Week 8 | -0.966 (-1.056 to -0.875) | -0.360 (-0.450 to -0.270) |
| Runny Nose Week 12 | -1.075 (-1.173 to -0.976) | -0.467 (-0.566 to -0.369) |
| Runny Nose Week 24 | -1.258 (-1.363 to -1.153) | -0.464 (-0.571 to -0.358) |
| Runny Nose Week 36 | -1.353 (-1.466 to -1.240) | -0.467 (-0.583 to -0.351) |
| Runny Nose Week 48 | -1.448 (-1.561 to -1.336) | -0.410 (-0.528 to -0.292) |
| Runny Nose Week 52 | -1.429 (-1.545 to -1.313) | -0.400 (-0.523 to -0.277) |
| Postnasal Drip Week 2 | -0.252 (-0.310 to -0.195) | -0.153 (-0.210 to -0.096) |
| Postnasal Drip Week 4 | -0.552 (-0.633 to -0.472) | -0.230 (-0.310 to -0.150) |
| Postnasal Drip Week 8 | -0.806 (-0.898 to -0.715) | -0.336 (-0.428 to -0.244) |
| Postnasal Drip Week 12 | -0.916 (-1.015 to -0.816) | -0.388 (-0.488 to -0.288) |
| Postnasal Drip Week 24 | -1.084 (-1.194 to -0.974) | -0.418 (-0.529 to -0.306) |
| Postnasal Drip Week 36 | -1.175 (-1.290 to -1.061) | -0.441 (-0.559 to -0.322) |
| Postnasal Drip Week 48 | -1.189 (-1.307 to -1.071) | -0.376 (-0.498 to -0.253) |
| Postnasal Drip Week 52 | -1.177 (-1.294 to -1.060) | -0.348 (-0.471 to -0.225) |
| Headache Week 2 | -0.259 (-0.318 to -0.199) | -0.185 (-0.245 to -0.126) |
| Headache Week 4 | -0.414 (-0.489 to -0.340) | -0.294 (-0.369 to -0.220) |
| Headache Week 8 | -0.673 (-0.753 to -0.594) | -0.382 (-0.461 to -0.303) |
| Headache Week 12 | -0.753 (-0.842 to -0.665) | -0.439 (-0.528 to -0.350) |
| Headache Week 24 | -0.870 (-0.970 to -0.771) | -0.470 (-0.571 to -0.369) |
| Headache Week 36 | -0.928 (-1.034 to -0.821) | -0.387 (-0.496 to -0.278) |
| Headache Week 48 | -0.962 (-1.075 to -0.849) | -0.361 (-0.476 to -0.245) |
| Headache Week 52 | -0.941 (-1.056 to -0.825) | -0.341 (-0.459 to -0.222) |
| Facial Pain Week 2 | -0.250 (-0.310 to -0.190) | -0.171 (-0.231 to -0.111) |
| Facial Pain Week 4 | -0.438 (-0.514 to -0.363) | -0.276 (-0.352 to -0.201) |
| Facial Pain Week 8 | -0.723 (-0.806 to -0.640) | -0.368 (-0.450 to -0.285) |
| Facial Pain Week 12 | -0.801 (-0.888 to -0.713) | -0.438 (-0.526 to -0.350) |
| Facial Pain Week 24 | -0.957 (-1.056 to -0.858) | -0.494 (-0.594 to -0.393) |
| Facial Pain Week 36 | -1.000 (-1.106 to -0.893) | -0.396 (-0.506 to -0.286) |
| Facial Pain Week 48 | -1.010 (-1.125 to -0.895) | -0.358 (-0.476 to -0.239) |
| Facial Pain Week 52 | -1.002 (-1.118 to -0.886) | -0.316 (-0.436 to -0.197) |
| Facial Pressure Week 2 | -0.276 (-0.338 to -0.215) | -0.170 (-0.232 to -0.109) |
| Facial Pressure Week 4 | -0.509 (-0.587 to -0.431) | -0.277 (-0.355 to -0.199) |
| Facial Pressure Week 8 | -0.778 (-0.866 to -0.689) | -0.373 (-0.461 to -0.284) |
| Facial Pressure Week 12 | -0.840 (-0.929 to -0.750) | -0.460 (-0.549 to -0.370) |
| Facial Pressure Week 24 | -0.987 (-1.087 to -0.887) | -0.501 (-0.603 to -0.400) |
| Facial Pressure Week 36 | -1.039 (-1.148 to -0.930) | -0.400 (-0.512 to -0.288) |
| Facial Pressure Week 48 | -1.093 (-1.210 to -0.975) | -0.379 (-0.499 to -0.258) |
| Facial Pressure Week 52 | -1.081 (-1.200 to -0.962) | -0.342 (-0.464 to -0.220) |
| Difficulty with Sense of Smell Week 2 | -0.126 (-0.164 to -0.088) | -0.037 (-0.074 to 0.001) |
| Difficulty with Sense of Smell Week 4 | -0.416 (-0.483 to -0.348) | -0.053 (-0.120 to 0.014) |
| Difficulty with Sense of Smell Week 8 | -0.804 (-0.897 to -0.711) | -0.107 (-0.200 to -0.015) |
| Difficulty with Sense of Smell Week 12 | -0.909 (-1.015 to -0.804) | -0.208 (-0.313 to -0.103) |
| Difficulty with Sense of Smell Week 24 | -1.078 (-1.195 to -0.961) | -0.275 (-0.392 to -0.158) |
| Difficulty with Sense of Smell Week 36 | -1.101 (-1.221 to -0.980) | -0.300 (-0.422 to -0.177) |
| Difficulty with Sense of Smell Week 48 | -1.242 (-1.364 to -1.121) | -0.289 (-0.413 to -0.166) |
| Difficulty with Sense of Smell Week 52 | -1.261 (-1.382 to -1.139) | -0.255 (-0.378 to -0.133) |
| Difficulty with Sleeping Week 2 | -0.340 (-0.399 to -0.281) | -0.188 (-0.247 to -0.129) |
| Difficulty with Sleeping Week 4 | -0.655 (-0.738 to -0.572) | -0.284 (-0.367 to -0.202) |
| Difficulty with Sleeping Week 8 | -0.994 (-1.084 to -0.904) | -0.454 (-0.544 to -0.364) |
| Difficulty with Sleeping Week 12 | -1.081 (-1.177 to -0.984) | -0.495 (-0.591 to -0.398) |
| Difficulty with Sleeping Week 24 | -1.262 (-1.365 to -1.159) | -0.516 (-0.621 to -0.411) |
| Difficulty with Sleeping Week 36 | -1.307 (-1.420 to -1.194) | -0.520 (-0.637 to -0.403) |
| Difficulty with Sleeping Week 48 | -1.307 (-1.427 to -1.188) | -0.469 (-0.595 to -0.342) |
| Difficulty with Sleeping Week 52 | -1.317 (-1.436 to -1.197) | -0.454 (-0.580 to -0.327) |
| Difficulty with Daily Activities week 2 | -0.282 (-0.340 to -0.225) | -0.183 (-0.240 to -0.126) |
| Difficulty with Daily Activities week 4 | -0.504 (-0.582 to -0.425) | -0.294 (-0.372 to -0.216) |
| Difficulty with Daily Activities week 8 | -0.836 (-0.926 to -0.747) | -0.408 (-0.497 to -0.319) |
| Difficulty with Daily Activities week 12 | -0.948 (-1.043 to -0.853) | -0.469 (-0.564 to -0.374) |
| Difficulty with Daily Activities week 24 | -1.135 (-1.242 to -1.028) | -0.520 (-0.628 to -0.412) |
| Difficulty with Daily Activities week 36 | -1.201 (-1.316 to -1.085) | -0.509 (-0.629 to -0.389) |
| Difficulty with Daily Activities week 48 | -1.213 (-1.334 to -1.091) | -0.440 (-0.568 to -0.313) |
| Difficulty with Daily Activities week 52 | -1.212 (-1.334 to -1.090) | -0.414 (-0.542 to -0.285) |
Nasal peak inspiratory flow evaluation represents a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute.
| Liters per minute. | Tezepelumab | Placebo |
|---|---|---|
| Week 12 | 21.860 (10.888 to 32.831) | -1.695 (-12.313 to 8.923) |
| Week 24 | 29.437 (17.500 to 41.373) | 6.258 (-5.563 to 18.080) |
| Week 36 | 11.228 (0.875 to 21.581) | -4.941 (-15.570 to 5.687) |
| Week 52 | 22.551 (11.467 to 33.635) | 0.489 (-10.973 to 11.952) |
The Asthma Control Questionnaire is an assessment of asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short acting beta-agonist use). Participants are asked to recall their level of asthma control during the previous week by responding to one bronchodilator use question and 5 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).
| Score | Tezepelumab | Placebo |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire-6 at Week 52. | -1.203 (-1.334 to -1.072) | -0.815 (-0.967 to -0.663) |
Serum concentrations of tezepelumab through Week 64. Logarithm transformation was used when calculating geometric mean of serum concentrations. The results were transformed back to original scale.
| μg/mL | Tezepelumab | Placebo |
|---|---|---|
| Baseline | NA ± NA | — |
| Week 4 | 12.165 ± 35.9 | — |
| Week 12 | 21.496 ± 40.8 | — |
| Week 24 | 23.994 ± 43.0 | — |
| Week 36 | 25.237 ± 45.4 | — |
| Week 52 | 24.352 ± 43.7 | — |
| Week 64 | 2.449 ± 103.1 | — |
Anti-drug antibodies (ADA) responses at baseline and post-baseline. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.
| Participants | Tezepelumab | Placebo |
|---|---|---|
| ADA prevalence | 10 | 19 |
| ADA positive at baseline only | 2 | 1 |
| Treatment-induced ADA positive | 6 | 12 |
| Treatment-boosted ADA positive | 0 | 0 |
| Treatment emergent ADA (ADA incidence) | 6 | 12 |
| Both baseline and at least one post-baseline ADA positive | 2 | 4 |
| ADA persistently positive | 4 | 11 |
| ADA transiently positive | 4 | 7 |
| TE-ADA positive with maximum titre > median of maximum titres | 1 | 2 |
| ADA positive at baseline (regardless of post-baseline) | 4 | 2 |
| Any post-baseline ADA positive | 8 | 18 |
| nAb positive at baseline and/or post-baseline (nAb prevalence) | 2 | 2 |
| Treatment-induced nAb positive (nAb incidence) | 1 | 2 |
Anti-drug antibodies (ADA) responses at baseline and post-baseline. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.
| Participants | Tezepelumab | Placebo |
|---|---|---|
| ADA prevalence | 3 | 4 |
| ADA positive at baseline only | 1 | 0 |
| Treatment-induced ADA positive | 2 | 3 |
| Treatment-boosted ADA positive | 0 | 0 |
| Treatment emergent ADA (ADA incidence) | 2 | 3 |
| Both baseline and at least one post-baseline ADA positive | 0 | 1 |
| ADA persistently positive | 1 | 2 |
| ADA transiently positive | 1 | 2 |
| TE-ADA positive with maximum titre > median of maximum titres | 1 | 0 |
| ADA positive at baseline (regardless of post-baseline) | 1 | 1 |
| Any post-baseline ADA positive | 2 | 4 |
| nAb positive at baseline and/or post-baseline (nAb prevalence) | 1 | 0 |
| Treatment-induced nAb positive (nAb incidence) | 1 | 0 |
Collected over From visit 1 (the date of the first study procedure) until end of study up to week 76.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Period | 0/408 (0%) | 0/408 (0%) | 20/408 (4.9%) |
| Tezepelumab | 0/203 (0%) | 11/203 (5.4%) | 119/203 (58.6%) |
| Placebo | 1/205 (0.5%) | 14/205 (6.8%) | 119/205 (58%) |
| Event | Run-in Period | Tezepelumab | Placebo |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/408 | 0/203 | 2/205 |
| AppendicitisInfections and infestations | 0/408 | 1/203 | 0/205 |
| Arthritis bacterialInfections and infestations | 0/408 | 1/203 | 0/205 |
| COVID-19 pneumoniaInfections and infestations | 0/408 | 1/203 | 0/205 |
| Escherichia urinary tract infectionInfections and infestations | 0/408 | 1/203 | 0/205 |
| Pneumonia bacterialInfections and infestations | 0/408 | 1/203 | 0/205 |
| Pulmonary tuberculosisInfections and infestations | 0/408 | 1/203 | 0/205 |
| Femur fractureInjury, poisoning and procedural complications | 0/408 | 1/203 | 0/205 |
| Invasive lobular breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/408 | 1/203 | 0/205 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/408 | 1/203 | 0/205 |
| Event | Run-in Period | Tezepelumab | Placebo |
|---|---|---|---|
| Chronic rhinosinusitis with nasal polypsRespiratory, thoracic and mediastinal disorders | 1/408 | 16/203 | 56/205 |
| COVID-19Infections and infestations | 1/408 | 55/203 | 44/205 |
| NasopharyngitisInfections and infestations | 4/408 | 45/203 | 23/205 |
| Upper respiratory tract infectionInfections and infestations | 1/408 | 23/203 | 13/205 |
| HeadacheNervous system disorders | 11/408 | 19/203 | 16/205 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/408 | 14/203 | 7/205 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/408 | 1/203 | 12/205 |
| PharyngitisInfections and infestations | 0/408 | 11/203 | 1/205 |
All participants who were randomized and received any IP were included in the full analysis set.
| Age, Categorical(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 174 | 179 | 353 |
| >=65 years | 29 | 26 | 55 |
| Age, Continuous(years) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Mean | 50.1 ± 13.60 | 49.4 ± 13.69 | 49.7 ± 13.63 |
| Sex: Female, Male(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Female | 77 | 65 | 142 |
| Male | 126 | 140 | 266 |
| Ethnicity (NIH/OMB)(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 11 | 22 |
| Not Hispanic or Latino | 192 | 194 | 386 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Black or African American | 3 | 3 | 6 |
| White | 150 | 149 | 299 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 46 | 51 | 97 |
| Other | 4 | 2 | 6 |
| Not reported | 0 | 0 | 0 |
Showing the first 100 of 112 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2021 to primary completion in Sep 2024, 41 months.
Results were first posted in Jan 2026, 1 year 4 months after primary completion.
Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 41 months is above that.
Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab